Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:52:17.911Z.
Calculation as of: 2026-10-06T14:52:17.911Z.
Quote observation: 2026-10-06T14:50:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.46B
PS Ratio
0.78
TTM Avg
0.80
3Y Avg
0.61
5Y Avg
0.64
Market Cap
$1.44B
PS Ratio
71.99
TTM Avg
162.26
3Y Avg
112.18
5Y Avg
112.18
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.46B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.78 | 0.80 | 0.61 | 0.64 |
| Certara, Inc. (CERT)vs › | $1.49B | 3.65 | 3.01 | 4.89 | 7.22 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 14.16 | 10.39 | 7.65 | 6.59 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | 71.99 | 162.26 | 112.18 | 112.18 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 6.00 | 6.28 | 11.75 | 20.01 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 1.80 | 1.16 | 0.80 | 3.00 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 3.46 | 4.33 | 4.05 | 3.79 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
